Han Kichang, Kim Jin Hyoung, Kim Gun Ha, Kim Ji Hoon, Kim So Yeon, Park Seong Ho, Moon Sungmo, Kwon Joon Ho, Kim Gyoung Min, Lee So Jung, Won Hyung Jin, Shin Yong Moon
Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea.
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 138-736, Korea.
Eur Radiol. 2024 Mar;34(3):1578-1586. doi: 10.1007/s00330-023-10165-6. Epub 2023 Aug 30.
To compare the safety and efficacy of RFA for single HCCs ≤ 3 cm in subcapsular versus nonsubcapsular locations using a propensity score matched analysis.
This retrospective study included patients with solitary HCCs ≤ 3 cm in size who underwent percutaneous RFA from 2005 to 2015 as initial treatment at two large-volume liver centers. Patients were divided into two groups, consisting of those with subcapsular and nonsubcapsular tumor locations. Complications, local tumor progression (LTP), and overall survival (OS) were compared in these two groups before and after propensity score matching (PSM).
The study population consisted of 964 patients (712 men [74%]) of mean age 58.3 years. Of these 964 patients, 561 (58%) had nonsubcapsular and 403 (42%) had subcapsular HCCs. PSM generated 402 pairs of patients. Major complication rate was low, but significantly higher in the subcapscular group (p = 0.047). Rates of technical effectiveness in these two groups were 99% and 98%, respectively (p = 0.315). However, during follow-up, cumulative 1-, 3-, 5-, and 10-year LTP and OS rates did significantly differ in both entire and PSM cohorts, resulting in the latter 8%, 15%, 20%, and 26% in the nonsubcapsular group vs. 13%, 24%, 30%, and 31% in the subcapsular group (p = 0.015), and 99%, 91%, 80%, and 59% vs. 98%, 85%, 73%, and 50% in the two groups (p = 0.004), respectively.
Rates of major complications, LTP, and OS differed significantly following first-line RFA treatment of single HCCs ≤ 3 cm in favor of the nonsubcapsular locations.
This large-scale study provides evidence that radiofrequency ablation for small (≤ 3 cm) hepatocellular carcinomas is safer and more effective in nonsubcapsular location than in subcapsular location.
• There exist conflicting outcomes on the effectiveness of RFA for early HCC depending on tumor location. • Rate of local tumor progression was significantly higher in the subcapsular hepatocellular carcinomas. • Overall survival rate was significantly poorer in the subcapsular hepatocellular carcinomas.
采用倾向评分匹配分析比较射频消融术(RFA)治疗直径≤3 cm的单发性肝细胞癌(HCC)时,肿瘤位于肝包膜下与非肝包膜下的安全性和疗效。
这项回顾性研究纳入了2005年至2015年在两个大容量肝脏中心接受经皮RFA作为初始治疗的直径≤3 cm的单发HCC患者。患者分为两组,分别为肿瘤位于肝包膜下和非肝包膜下的患者。在倾向评分匹配(PSM)前后,比较两组的并发症、局部肿瘤进展(LTP)和总生存期(OS)。
研究人群包括964例患者(712例男性[74%]),平均年龄58.3岁。在这964例患者中,561例(58%)的肿瘤位于非肝包膜下,403例(42%)的肿瘤位于肝包膜下。PSM产生了402对患者。主要并发症发生率较低,但肝包膜下组显著更高(p = 0.047)。两组的技术有效率分别为99%和98%(p = 0.315)。然而,在随访期间,整个队列和PSM队列中1年、3年、5年和10年的累积LTP率和OS率在两组中确实存在显著差异,非肝包膜下组分别为8%、15%、20%和26%,而肝包膜下组为13%、24%、30%和31%(p = 0.015),两组的OS率分别为99%、91%、80%和59%以及98%、85%、73%和50%(p = 0.004)。
一线RFA治疗直径≤3 cm的单发性HCC后,主要并发症、LTP和OS率存在显著差异,非肝包膜下位置更具优势。
这项大规模研究提供了证据,表明对于小(≤3 cm)肝细胞癌,射频消融术在非肝包膜下位置比在肝包膜下位置更安全、更有效。
• 根据肿瘤位置,RFA治疗早期HCC的有效性存在相互矛盾的结果。• 肝包膜下肝细胞癌的局部肿瘤进展率显著更高。• 肝包膜下肝细胞癌的总生存率显著更低。